PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors
Article in Cellular Oncology (September 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Implications of c-Myc in the pathogenesis and treatment efficacy of urological cancers
Article in Pathology - Research and Practice (June 2024)
Research Progress of PSMD2 in Cancer
Article in Medical Diagnosis (January 2024)